证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|---------------|-------------|---------------| | | | | 编号：2023007 | | | √特定对象调研 | □媒体采访 □ | 分析师会议 | | 投资者关系活动类别 | □新闻发布会 □ | 业绩说明会 | □路演活动 | √现场参观 □其他 参与单位名 称及人员 姓名 西部证券 陆伏葳；新华资产 张滢潭、杨帅、李浩、陈嘉桦、陈振 华；兴业证券 汪文博；民生加银 尹涛、郝梦娇、王泳鑫 时 间 2023 年 6 月 30 日 地 点 公司会议室+腾讯会议 上市公司接 待人员姓名 董事长、总经理宋侃先生 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、种植牙市场上半年整体恢复情况如何？ 答：以口腔种植牙相关产品的销售情况来看，今年 1、2 月份受到疫情放开、春 节假期的双重影响，销量同比大幅受挫，3 月份受部分民营口腔医院提前执行集采 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|---------------|-------------|---------------| | | | | 编号：2023006 | | | √特定对象调研 | □媒体采访 □ | 分析师会议 | | 投资者关系活动类别 | □新闻发布会 □ | 业绩说明会 | □路演活动 | √现场参观 □其他 深圳证券交易所 刘然、杨乔君；证券时报 黄翔；中泰证券 韩卓君、 参与单位名 称及人员 姓名 林琛；安信证券 董正、盖飞飞；投资者 李海霞、宋自磊、赵东华、 迟洪鹏等 26 人 时 间 2023 年 6 月 29 日 地 点 公司会议室 上市公司接 待人员姓名 董事长、总经理宋侃先生 投资者关系活动主要内容 一、公司介绍经营情况 正海生物成立于 2003 年，于 2017 年 5 月 16 日在深交所创业板上市，公司立足 再生医学领域，是一家致力于生物再生材料的研发、生产及销售为一体的高新技术 企业。目前已上市产品有口腔修复 ...

证券代码：300653 证券简称：正海生物 | --- | --- | --- | --- | |--------------------|---------------|-------------|---------------| | | | | 编号：2023005 | | | √特定对象调研 | □媒体采访 □ | 分析师会议 | | 投资者关系活动类别 | □新闻发布会 □ | 业绩说明会 | □路演活动 | √现场参观 □其他 参与单位名 称及人员 姓名 博时基金 柴文超；天风证券 张雪；华能信托 田维锋；冲积资产 任 毅；汇森投资 庞雨东；中隐基金 王进 唐臻宁 时 间 2023 年 6 月 5 日 地 点 公司会议室 上市公司接 待人员姓名 董事长、总经理宋侃先生 烟台正海生物科技股份有限公司 投资者关系活动记录表 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、种植牙市场的恢复情况如何？ 答：以口腔种植牙相关产品的销售情况来看，今年 1、2 月份受到疫情放开、春 节假期的双重影响，销量同比大幅受挫，3 月份受部分民营口腔医院提前执行集采 后价格的影响，公司产品销 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2023004 | --- | --- | --- | |--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------- ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------------|-----------------------|---------------| | | | | 编号：2023003 | | | | | | | 投资者关系活动类别 | □新闻发布会 | □业绩说明会 □路演活动 | | □现场参观 □其他 东北证券 方心宇；国泰基金 姜英；源峰基金 耿华；新华基金 赵 参与单位名 称及人员 姓名 东宇；工银瑞信 丁洋；民生加银 郝梦娇；星石投资 朱宇希；东吴 基金 吴佳歆；长江养老 叶小桃；淳厚基金 严定安；九泰基金 王 宇鸿；太平基金 赵超；嘉实基金 程佳 时 间 2023 年 5 月 26 日 地 点 公司会议室+腾讯会议 上市公司接 待人员姓名 董事长、总经理宋侃先生，副总经理张东刚先生 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、公司活性生物骨产品的进展情况如何？ 答：公司的活性生物骨产品正在做相关的转产验证工作 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------------|-----------------------|---------------| | | | | 编号：2023002 | | | | | | | 投资者关系活动类别 | □新闻发布会 | □业绩说明会 □路演活动 | | √现场参观 □其他 深圳市徐星私募 张东伟；杭州哲云私募 丁谢峰；个人投资者 徐方 参与单位名 称及人员 姓名 云、赵连平、姜荣光、刘凡、王居福、邹萍萍、陈建花、胡荣雁； 证券日报 彭春来、赵宁、赵彬彬、王僖等人 时 间 2023 年 5 月 10 日、2023 年 5 月 11 日 地 点 公司会议室 上市公司接 待人员姓名 董事长、总经理宋侃先生 投资者关系活动主要内容 本次活动主要采用解答提问的方式进行，主要内容如下： 1、公司的业绩及分红情况如何？ 答：回顾过去几年公司业绩保持稳定增长。2017 年至 2022 年，营业收入由 1.83 亿元增长至 4.33 亿元， ...

烟台正海生物科技股份有限公司 2023 年第一季度报告 证券代码：300653 证券简称：正海生物 公告编号：2023-031 烟台正海生物科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经过审计 □是 否 1 烟台正海生物科技股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 □会计政策变更 □会计差错更正 □同一控制下企业合并 其他原因 | | 本报告期 | 上年同期 | | 本报告期比上年同期 | | --- | --- | --- | --- | --- | | | | | | 增减（%） | | | | ...

Revenue and Financial Performance - The company's operating revenue for 2022 was ¥433,224,730.58, an increase of 8.26% compared to ¥400,175,251.94 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥185,436,805.06, reflecting a growth of 10.02% from ¥168,552,584.39 in 2021[28]. - The net profit after deducting non-recurring gains and losses was ¥172,608,159.41, up 7.29% from ¥160,878,004.21 in 2021[28]. - The net cash flow from operating activities increased by 13.06% to ¥187,838,040.27 in 2022 from ¥166,134,014.20 in 2021[28]. - Basic earnings per share rose by 36.17% to ¥1.28 in 2022, compared to ¥0.94 in 2021[28]. - Total assets at the end of 2022 reached ¥986,904,775.50, a 6.24% increase from ¥928,920,991.12 at the end of 2021[28]. - The net assets attributable to shareholders increased by 10.17% to ¥865,107,791.65 at the end of 2022 from ¥785,270,986.59 at the end of 2021[28]. - The company achieved a net profit of 185.44 million yuan in 2022, representing a year-on-year growth of 10.02%[49]. - Total revenue for 2022 reached 433.22 million yuan, an increase of 8.26% compared to the previous year[50]. Product Development and Market Position - The main revenue sources for the company are the oral repair membrane and absorbable dura (spinal) membrane patches, both of which have experienced rapid growth in recent years[5]. - The company is focused on regenerative medicine, aiming to develop innovative products to meet clinical needs[36]. - The company’s R&D efforts are aimed at developing new products, although the process is lengthy and involves significant investment[7]. - The company has successfully registered new products including "self-etching adhesive" and "active biological bone," expanding its product offerings[45]. - The company is currently conducting clinical trials for several key projects, including light-cured composite resin and calcium silicate bioceramic bone repair materials[79]. - The company is in the process of launching new products, including a breast patch for reconstruction and a uterine cavity repair membrane[79]. - The company is actively developing new products and technologies, with a focus on enhancing the efficacy of its active biological bone and skin repair membrane[110]. Risk Management and Challenges - The company emphasizes the importance of enhancing management capabilities and market expansion to mitigate potential risks from external changes[5]. - The company is focused on addressing risks related to product concentration and external environmental changes, which could affect future growth[5]. - Regulatory changes and external environment shifts, including centralized procurement policies, present ongoing challenges for maintaining market competitiveness[105]. - The company faces risks due to a concentrated product portfolio, with a focus on regenerative medicine and ongoing development of new products like active biological bone and second-generation dura membranes[104]. - Product quality is critical, as any issues could adversely affect both health outcomes and the company's operations[106]. Governance and Management - The company has established a governance structure that ensures compliance with relevant laws and regulations, enhancing operational transparency and risk management[113]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[115]. - The company has maintained independence from its controlling shareholder in terms of assets, personnel, finance, and operations, achieving a "five independence" standard[117]. - The company has a strong management team with members holding advanced degrees and extensive experience in the biotechnology and pharmaceutical sectors[126]. - The company has appointed several independent directors with significant experience in finance and management to strengthen its governance[124]. Shareholder Engagement and Profit Distribution - The profit distribution plan approved by the board is a cash dividend of 6.00 RMB per 10 shares (including tax), with no bonus shares issued[7]. - The company aims to distribute at least 20% of the annual distributable profit as cash dividends, increasing to 10% if there are significant investment plans or cash expenditures[145]. - The company has maintained a stable profit distribution policy, with adjustments requiring thorough research and approval from the board and shareholders[150]. - The board of directors will consider shareholder feedback, especially from minority shareholders, when proposing cash dividend plans[148]. - The company distributed a cash dividend of RMB 105.6 million to shareholders, with a distribution of RMB 8.80 per 10 shares[166]. Market Expansion and Sales Strategy - The company has successfully participated in volume-based procurement in six provinces, including Jiangsu and Shandong, without significant pressure on performance, although future expansions of procurement may impact growth[5]. - The company is focusing on expanding its market presence and product applications, particularly in the fields of oral repair and neurosurgery[110]. - The company actively participated in around 750 academic activities to enhance market presence and brand recognition[52]. - The company has over 1,100 distributors nationwide, ensuring a broad marketing network and strong brand recognition in the market[62]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its product offerings[110]. Quality Management and Compliance - The company has established a comprehensive quality management system, achieving ISO 13485 and ISO 9001 certifications[64]. - The quality management system maintained a 100% pass rate for product inspections, ensuring stable and effective quality management throughout the reporting period[57]. - The company has implemented a supplier evaluation management system, conducting annual assessments to control product quality from the source[171]. - The company has established a monitoring group for adverse events related to product quality, ensuring rapid response and consumer protection[170]. - The internal control system has been strengthened to ensure compliance with laws and regulations, enhancing risk management and operational efficiency[155]. Employee Development and Welfare - The total number of employees at the end of the reporting period is 376, with 163 in production, 105 in sales, 61 in technical roles, 7 in finance, and 40 in administration[140]. - The company has established a comprehensive employee welfare system, providing nearly 20 types of benefits[168]. - The company has conducted training programs to enhance employee skills and support business innovation[168]. - The company emphasizes continuous and stable profit distribution policies, prioritizing cash dividends over stock dividends[144]. Environmental Responsibility - The company has implemented various environmental protection measures, including the installation of pollution control equipment and the use of natural gas boilers[162]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[163]. - Environmental protection measures include the installation of various eco-friendly equipment, ensuring compliance with local environmental regulations[171].

2022 年度网上业绩说明会 证券代码：300653 证券简称：正海生物 公告编号：2023-024 欢迎广大投资者积极参与！ 特此公告。 烟台正海生物科技股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）2022 年年度报告全文 及摘要已于 2023 年 4 月 11 日刊登于中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）。为便于投资者能够进一步了解公司的生产经营情况， 公司将于 2023 年 4 月 12 日（周三）15:00-17:00 在机会宝和中国证券报·中证 网举办 2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式 举行，投资者可登录机会宝（https://n.jhbshow.com/live-text/2124749310 或扫描下 方二维码）和中证路演中心（https://www.cs.com.cn/roadshow/yjsmh/300653_2022/） 参与本年度业绩说明会 ...